Literature DB >> 10746008

[The impact of regulation of postprandial glucose in practice].

B Vergès.   

Abstract

Meal and post-meal periods define a post-prandial state covering about 66% of day duration and characterized by a glucose and other nutrients influx into the blood flow. Post-prandial hyperglycemia can be an early feature of glucose intolerance, indicating a failure to control for post-prandial glucose load, but mostly characterizes type 2 diabetes, reflecting quantitative and/or qualitative abnormalities in insulin secretion by pancreatic beta cells. Post-prandial hyperglycemia contributes to raise glycated hemoglobin (HbA1c) level, which as an indicator of total glycemic load, is tightly correlated with the incidence of micro- and macroangiopathy in type 2 diabetes. It can induce or deteriorate fasting hyperglycemia and be associated with coagulation activation and/or lipid metabolism abnormalities, the latter being considered as cardiovascular risk factors, even in non diabetic populations. Therefore caring for post-prandial glucose regulation is particularly relevant in glucose intolerant and type 2 diabetic patients. Accordingly, several pharmacological treatments have been designed, among which repaglinide recently emerged as an efficient, safe and convenient regulator of post-prandial glycemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10746008

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  2 in total

1.  Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.

Authors:  Peter Bramlage; Christiane Binz; Anselm K Gitt; Michael Krekler; Tanja Plate; Evelin Deeg; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2010-09-16       Impact factor: 9.951

2.  Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics.

Authors:  Shahram Haddadinezhad; Nargess Ghazaleh
Journal:  Int J Diabetes Dev Ctries       Date:  2010-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.